Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

24.10.2024

As competition heats up, Novo Nordisk’s share price declines

Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

Subscribe Log in

diabetes treatment, Eli Lilly, GLP-1 drugs, healthcare trends, mounjaro, Novo Nordisk, obesity market, ozempic, wegovy, weight loss drugs, Zepbound

More from Health Matters

06.11.2026

Pharmaceutical Sovereignty Put to the Test by Ebola

Pharmaceutical sovereignty is back in focus as Ebola spreads in the DRC. See how pooled procurement and shared regulation could secure supplies.

05.11.2026

Rare Disease Funding in Focus After KeyHealth Ruling

Rare disease funding is under scrutiny after the KeyHealth ruling. See how schemes could share the cost of treatments such as Ultomiris.

05.11.2026

Essential Medicine Shortages Hit Public Hospitals

Essential medicine shortages threaten 165 public sector products in South Africa. See what is disrupting supply and how the department is responding.